New-generation drug-eluting stents: Focus on Xience V® everolimus-eluting stent and Resolute® zotarolimus-eluting stent

Journal of Interventional Cardiology

Volumn 26, Issue 3, 2013, Pages 278-286

  Van Dyck, Christophe J ^a,b   Hoymans, Vicky Y ^a,b   Haine, Steven ^a,b   Vrints, Christiaan J ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

'TAXUS'; ALLOY; CHROMIUM; COBALT; CYPHER DRUG; EVEROLIMUS; FK 506 BINDING PROTEIN; PACLITAXEL; POLYMER; RAPAMYCIN; RESOLUTE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ARTERY INTIMA PROLIFERATION; ARTICLE; BIOCOMPATIBILITY; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DESIGN; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; HEART DEATH; HIGH RISK PATIENT; HYPERPLASIA; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SCANNING ELECTRON MICROSCOPY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

ANGIOPLASTY, BALLOON, CORONARY; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84879014808     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12028     Document Type: Article

References (64)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. (Pubitemid 34586912)
2. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537-1545. (Pubitemid 36437930)
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008. (Pubitemid 46376800)
4. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591. (Pubitemid 44881238)
5. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510. (Pubitemid 46986103)
6. Banerjee S, Xu H, Fuh E, et al. Endothelial progenitor cell response to antiproliferative drug exposure. Atherosclerosis 2012; 225: 91-98.
7. Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (Trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with ballOON angioplasty). JACC Interv 2011; 4: 14-23.
8. Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial. Lancet 2012; 380: 1396-1405.
9. Costa MA, Simon DI., Molecular basics of restenosis and drug-eluting stents. Circulation 2005; 111: 2257-2273. (Pubitemid 40632443)
10. Lavigne MC, Grimsby JL, Eppihimer MJ., Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: Inhibition of human coronary artery smooth muscle cell proliferation, but not migration. J Cardiovasc Pharmacol 2012; 59: 165-174.
11. Grube E, Buellesfeld L., Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med 2004; 5 (Suppl 2): S3-S8. (Pubitemid 38811481)
12. Kirchner RM, Abbott JD., Update on the everolimus-eluting coronary stent system: Results and implications from the SPIRIT clinical trial program. Vasc Health Risk Manag 2009; 5: 1089-1097.
13. Talarico GP, Burzotta F, Trani C, et al. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents, the impact of polymer coating in DES technology. Catheter Cardiovasc Interv 2013; 81: 268-273.
14. Udipi K, Chen M, Cheng P, et al. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A 2008; 85: 1064-1071. (Pubitemid 351717975)
15. Räber L, Windecker S., Current status of drug-eluting stents. Cardiovasc Ther 2011; 29: 176-189.
16. Suzuki Y, Yeung AC, Ikeno F., The pre-clinical animal model in the translational research of interventional cardiology. JACC Cardiovasc Interv 2009; 2: 373-383.
17. Han Y, Xu K, Yan C., Translational research on novel drug-eluting stents in percutaneous coronary intervention. Front Med 2011; 5: 395-400.
18. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342. (Pubitemid 352001347)
19. Nakazawa G, Nakano M, Otsuka F, et al. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv 2011; 4: 38-46.
20. Van Dyck CJ, Hoymans VY, Bult H, et al. Resolute and Xience V polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model. Catheter Cardiovasc Interv 2012. doi: 10.1002/ccd.24595
21. Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Eurointervention 2005; 1: 58-65.
22. Serruys PW, Ruygrok P, Neuzner J, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. Eurointervention 2006; 2: 286-294.
23. Ruygrok PN, Desaga M, Van Den Branden F, et al. One year clinical follow-up of the Xience V everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: The SPIRIT II study. Eurointervention 2007; 3: 315-320.
24. Garg S, Serruys PW, Miquel-Hebert K., et al. Four-year clinical follow-up of the Xience V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial. Catheter Cardiovasc Interv 2011; 77: 1012-1017.
25. Wiemer M, Serruys PW, Miquel-Hebert K, et al. Five-year long-term clinical follow-up of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT First trial. Catheter Cardiovasc Interv 2010; 75: 997-1003.
26. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913. (Pubitemid 351574920)
27. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009; 119: 680-686.
28. Applegate RJ, Yaqub M, Hermiller JB, et al. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III trial). Am J Cardiol 2011; 107: 833-840.
29. Nikolsky E, lansky AJ, Sudhir K, et al. SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009; 158: 520-526.
30. Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (clinical evaluation of the Xience V everolimus eluting coronary stent system) IV trial. J Am Coll Cardiol 2011; 58: 19-25.
31. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375: 201-209.
32. Smits PC, Kedhi E, Royaards KJ, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (comparison of the evorolimus eluting Xience V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: A randomized open label trial). J Am Coll Cardiol 2011; 58: 11-18.
33. Grube E, Chevalier B, Smits P, et al. The SPIRIT V study: A clinical evaluation of the Xience V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. JACC Cardiovasc Interv 2011; 4: 168-175.
34. Nakazawa G, Finn AV, John MC, et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: 36M-44M.
35. Kim JW, Seo HS, Park JH, et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus-versus a sirolimus-eluting stent: Differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009; 53: 1653-1659.
36. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55: 543-554.
37. Leon MB, Nikolsky E, Cutlip DE, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial. JACC Cardiovasc Interv 2010; 3: 1043-1050.
38. Kandzari DE, Mauri L, Popma JJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR II (a randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 2011; 4: 543-550.
39. Chen KY, Rha SW, Wang L, et al. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: A propensity score-matched analysis. J Am Coll Cardiol Intv 2012; 5: 936-945.
40. Meridith IT, Worthley S, Whitbourn R, et al. Clinical and angiographic results with the next-generation Resolute stent system: A prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009; 2: 977-985.
41. Mauri L, Leon MB, Yeung AC, et al. Rationale and design of the clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial). Am Heart J 2011; 161: 807-814.
42. Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: The RESOLUTE US clinical trial. J Am Coll Cardiol 2011; 57: 1778-1783.
43. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136-146.
44. Gutiérrez-Chico JL, van Geuns RJ, Regar E, et al. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. A fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: An optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J 2011; 32: 2454-2463.
45. Silber S, Windecker S, Vranckx P, et al. Unrestricted randomized use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011; 377: 1241-1247.
46. Neumann FJ, Widimsky P, Belardi JA., One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. Eurointervention 2012; 7: 1181-1188.
47. Bangalore S, Kumar S, Fusaro M, et al. Short and long-term outcomes with drug-eluting and bare-metal coronary stents: A mixed-treatment comparison analysis of 117 762 patient-year of follow-up from randomized trials. Circulation 2012; 125: 2873-2891.
48. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of "new-generation" drug-eluting stents: A report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33: 606-613.
49. Von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus Everolimus-eluting Xience V stents in real-world patients: The TWENTE trial. J Am Coll Cardiol 2012; 59: 1350-1361.
50. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-1402.
51. Kereiakes DJ, Cutlip DE, Applegate RJ, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: Results from the SPIRIT IV clinical trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system). J Am Coll Cardiol 2010; 56: 2084-2089.
52. Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011; 124: 893-900.
53. Grube E, Chevalier B, Guagliumi G, et al. The SPIRIT V diabetic study: A randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs. the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J 2012; 163: 867-875.
54. Jensen LO, Thayssen P, Junker A, et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). Am J Cardiol 2012; 110: 1585-1591.
55. Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: Mixed treatment comparison analysis of 22,844 patient years of follow-up from randomized trials. BMJ 2012; 345: e5170. doi: 10.1136/bmj.e5170
56. Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomized controlled trial. Lancet 2012; 380: 1482-1490.
57. Sudhir K, Hermiller JB, Naidu SS, et al. Clinical outcomes in real-world patients with acute myocardial infarction receiving Xience V (®) everolimus-eluting stents: One-year results from the Xience V USA study. Catheter Cardiovasc Interv 2012; November 21. doi: 10.1002/ccd.24749
58. Romagnoli E, Godino C, Ielasi A, et al. Resolute Italian study in all comers: Immediate and one-year outcomes. Catheter Cardiovasc Interv 2012; 79: 567-574.
59. Stefanini GG, Serruys PW, Silber S, et al. The impact of patient lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the RESOLUTE All Comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2011; 57: 2221-2232.
60. Tomai F, Petrolini A, de Luca L, et al. Rationale and design of the randomized comparison of Xience V and Multilink Vision coronary stents in the same multivessel patient with chronic kidney disease (RENAL-DES) study. J Cardiovasc Med 2010; 11: 310-317.
61. Buchanan GL, Basavarajaiah S, Chieffo A., Stent thrombosis: Incidence, predictors and new technologies. Thrombosis 2012. doi: 10.1155/2012/956962
62. Zhang L, Yuan J, Liu G, et al. One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease. J Interv Cardiol 2012; 25: 604-610.
63. Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The ABSORB trial. Eurointervention 2012; 7: 1060-1061.
64. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578-1588.